Prosecution Insights
Prosecution Insights
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| No statute on record | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALLEN, SARAH ELIZABETH | 1 | 61.9% | +44.4% |
| VIJAYARAGHAVAN, JAGAMYA NMN | 1 | 67.7% | +39.0% |
| LEITH, NANCY J | 1 | 74.7% | +43.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17585694 | METHODS AND PRODUCTS FOR PRODUCING ENGINEERED MAMMALIAN CELL LINES WITH AMPLIFIED TRANSGENES | LEITH, NANCY J | 132d overdue |
| 17712864 | NUCLEIC ACID MOLECULES ENCODING AN ENGINEERED ANTIGEN RECEPTOR AND AN INHIBITORY NUCLEIC ACID MOLECULE AND METHODS OF USE THEREOF | VIJAYARAGHAVAN, JAGAMYA NMN | 60d overdue |
| 17998419 | SELF-LIMITING VIRAL VECTORS ENCODING NUCLEASES | ALLEN, SARAH ELIZABETH | 72d |
| Art Unit | Apps |
|---|---|
| 1637 | 1 |
| 1633 | 1 |
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17998419 | SELF-LIMITING VIRAL VECTORS ENCODING NUCLEASES | ALLEN, SARAH ELIZABETH | 1637 | DPOther | Non-Final OA | 72d | Pending | Nov 10, 2022 |
| 17712864 | NUCLEIC ACID MOLECULES ENCODING AN ENGINEERED ANTIGEN RECEPTOR AND AN INHIBITORY NUCLEIC ACID MOLECULE AND METHODS OF USE THEREOF | VIJAYARAGHAVAN, JAGAMYA NMN | 1633 | §102 | Non-Final OA | 60d overdue | Pending | Apr 04, 2022 |
| 17585694 | METHODS AND PRODUCTS FOR PRODUCING ENGINEERED MAMMALIAN CELL LINES WITH AMPLIFIED TRANSGENES | LEITH, NANCY J | 1636 | Other | Non-Final OA | 132d overdue | Pending | Jan 27, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial